Registered Zambia · ZAMRA

Arteflo-40 Tablet

Propranolol 40 mg

149/011 Tablet Uncoated 40 mg INN generic

What it does

Propranolol is a beta blocker used to manage various health conditions by helping to lower heart rate and blood pressure.

Commonly used for: high blood pressure (hypertension), angina (chest pain), heart rhythm disorders (arrhythmias), prevention of migraine headaches …

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
149/011
Registration date
2026-09-10
Expiry date
2031-09-09
Status
Registered/Compliant
Active ingredient
Propranolol 40 mg
Dosage form
Tablet Uncoated
Strength
40 mg
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Leben Laboratories Pvt Ltd
Country of origin
India
Manufacturer location
M3P7+C4H, Midc Phase 3 and 4, MIDC, Shivar, Maharashtra 444104, India

Source: Zambia Medicines Regulatory Authority · fetched 2026-09-14 03:40:21 · updated 2026-09-17 03:40:28

Drug Interactions

7
Check interactions

Pharmacodynamic Warnings

Propranolol appears in TABLE 6: Drugs that cause bradycardia

Propranolol appears in TABLE 8: Drugs that cause hypotension

Severe (1)

Propranolol - increases exposure

Dacomitinib is predicted to markedly increase the exposure to propranolol. Avoid.

Severe Study

Moderate (3)

Propranolol - increases risk of cardiovascular adverse effects

Propafenoneincreasestheriskofcardiovascularadverse effectswhengivenwithbetablockers,non-selective (propranolol).Usewithcautionoravoid.rStudy →Alsosee TABLE6p.1518

Moderate Study

Propranolol - increases exposure

Eliglustat is predicted to increase the exposure to propranolol. Adjust dose.

Moderate Study

Propranolol - decreases exposure

Rifampicin decreases the exposure to beta blockers, non-selective (propranolol). Monitor and adjust dose.

Moderate Study

Unknown (3)

Propranolol - increases concentration

Fluvoxamine moderately increases the concentration of beta blockers, non-selective (propranolol).

Unknown Study

Rizatriptan - increases exposure

Propranolol slightly to moderately increases the exposure to triptans (rizatriptan). Adjust rizatriptan dose and separate administration by at least 2 hours, p. 519.

Unknown Study

Triptans - increases exposure

Propranolol slightly to moderately increases the exposure to triptans (rizatriptan). Adjust rizatriptan dose and separate administration by at least 2 hours, p. 519.

Unknown Study

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: exact

Disclaimer: This information is sourced from Zambia Medicines Regulatory Authority (Zambia). Always consult a qualified healthcare professional before using any medication.

About this medicine

Propranolol is a beta blocker used to manage various health conditions by helping to lower heart rate and blood pressure.

What it treats

  • high blood pressure (hypertension)
  • angina (chest pain)
  • heart rhythm disorders (arrhythmias)
  • prevention of migraine headaches
  • anxiety

How it works

Propranolol works by blocking certain receptors in the body, which helps to slow down the heart rate and reduce blood pressure.

Who it's for

This medication is suitable for adults who need help managing heart-related conditions or anxiety.

Drug class

Beta blockers

Cautions

  • • Be cautious if taking other medications that slow down the heart rate (bradycardia).
  • • Be careful with medications that can lower blood pressure (hypotension).

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: propranolol

BNF-referenced

Propranolol is a nonselective beta-adrenergic receptor antagonist classified under beta blockers. It is primarily used in the management of hypertension, anxiety, and other cardiovascular conditions. By blocking beta-adrenergic receptors, propranolol reduces heart rate, decreases myocardial contractility, and lowers blood pressure. It also exhibits anti-anxiety effects and is used for migraine prophylaxis.

Indications

  • Hypertension
  • Angina pectoris
  • Arrhythmias
  • Myocardial infarction prophylaxis
  • Migraine prophylaxis
  • Essential tremor
  • Anxiety disorders

Dosage

Children: Refer to the BNF for Children for specific dosing information, as paediatric doses vary based on condition and patient age.

Adults: The usual starting dose for hypertension is 40 mg twice daily, which may be increased based on clinical response. For migraine prophylaxis, the recommended dose is 80 mg daily, which can be divided or taken as a single dose.

Mechanism of action

Propranolol works by blocking β-adrenergic receptors, leading to vasoconstriction and inhibition of angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). This action induces apoptosis of endothelial cells and downregulates the renin-angiotensin-aldosterone system, contributing to its antihypertensive effects.

Pharmacodynamics

Propranolol has a long duration of action, allowing for once or twice daily dosing depending on the clinical indication. It effectively lowers blood pressure and heart rate. Abrupt discontinuation may lead to rebound hypertension, exacerbations of angina, or myocardial infarctions due to increased sympathetic activity.

Pharmacokinetics

Propranolol is well-absorbed after oral administration, with a bioavailability of approximately 25% due to first-pass metabolism in the liver. It is extensively metabolized in the liver, and its elimination half-life is about 3 to 6 hours. The drug is primarily excreted in urine as metabolites, and it has a volume of distribution of about 4 L/kg, indicating extensive tissue binding.

Contra-indications

  • Severe bradycardia
  • Second or third degree heart block
  • Cardiogenic shock
  • Asthma or history of bronchospasm
  • Severe peripheral arterial disease

Adverse effects

  • Fatigue
  • Dizziness
  • Bradycardia
  • Hypotension
  • Cold extremities
  • Sleep disturbances
  • Nausea
  • Diarrhea

Interactions

  • dacomitinib: Severe (increases exposure)
  • propafenone: Moderate (increases risk of cardiovascular adverse effects)
  • eliglustat: Moderate (increases exposure)
  • rifampicin: Moderate (decreases exposure)
  • triptans: Unknown (increases exposure)
  • rizatriptan: Unknown (increases exposure)
  • fluvoxamine: Unknown (increases concentration)

Precautions

  • Monitor heart rate and blood pressure regularly
  • Use with caution in patients with diabetes as it may mask hypoglycemia
  • Taper dosage gradually to avoid acute withdrawal symptoms
  • Use cautiously in patients with a history of depression

Pregnancy

Propranolol should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Propranolol is excreted in breast milk, and caution should be exercised when administered to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

  • Tablets (10 mg, 40 mg, 80 mg)
  • Oral solution (20 mg/5 ml)
  • Injectable solution (1 mg/ml)

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: Propranololhydrochloride

BNF-referenced

Propranolol hydrochloride is a non-selective beta-adrenergic antagonist primarily used in the management of hypertension, angina pectoris, arrhythmias, migraine prophylaxis, and thyrotoxicosis. It works by blocking the action of epinephrine and norepinephrine on beta-adrenergic receptors, leading to decreased heart rate, contractility, and blood pressure, as well as reduced myocardial oxygen demand.

Indications

  • Hypertension
  • Angina pectoris
  • Arrhythmias
  • Migraine prophylaxis
  • Thyrotoxicosis (adjunct therapy)
  • Phaeochromocytoma (with an alpha-blocker)
  • Prophylaxis of variceal bleeding in portal hypertension

Dosage

Adults: Initially 80 mg once daily, increased as needed in steps of 80 mg weekly

Mechanism of action

Propranolol acts by competitively inhibiting beta-adrenergic receptors, both beta-1 (located in the heart) and beta-2 (located in the lungs and vascular smooth muscle). This blockade decreases the effects of sympathetic stimulation, resulting in lowered heart rate, reduced myocardial contractility, and vasodilation, which collectively contribute to its antihypertensive and antianginal effects.

Pharmacodynamics

Propranolol exhibits dose-dependent effects on heart rate and blood pressure. At therapeutic doses, it reduces cardiac output and lowers blood pressure through decreased cardiac contractility and heart rate. It also has antiarrhythmic properties, preventing abnormal heart rhythms. Additionally, it may have central nervous system effects, contributing to its efficacy in migraine prophylaxis by inhibiting vasodilation and suppressing the release of inflammatory mediators.

Pharmacokinetics

Propranolol is well absorbed from the gastrointestinal tract, but it undergoes extensive first-pass metabolism in the liver, leading to variable bioavailability (approximately 25-35%). It is highly protein-bound (90-95%) and has a relatively short half-life of about 3-6 hours. Propranolol is metabolized primarily by CYP2D6 and CYP1A2, and its elimination half-life may be prolonged in patients with hepatic impairment. Renal function does not significantly affect the pharmacokinetics of propranolol.

Contra-indications

  • Asthma or severe chronic obstructive pulmonary disease
  • Bradycardia
  • Heart block greater than first degree
  • Cardiogenic shock
  • Severe peripheral arterial disease
  • Phaeochromocytoma (without an alpha-blocker)
  • Hypersensitivity to propranolol or any of its components

Adverse effects

  • Fatigue
  • Hypotension
  • Bradycardia
  • Dizziness
  • Nausea
  • Vomiting
  • Diarrhea
  • Insomnia
  • Nightmares
  • Depression
  • Sexual dysfunction
  • Cold extremities
  • Peripheral vasoconstriction
  • Worsening of asthma
  • Agranulocytosis
  • Thrombocytopenia
  • Psoriasis exacerbation

Interactions

  • Other antihypertensives
  • Calcium channel blockers (e.g., verapamil, diltiazem)
  • Digoxin
  • Insulin and oral hypoglycemics
  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Rifampicin
  • Cimetidine
  • Clonidine

Precautions

  • Caution in patients with diabetes mellitus due to potential hypoglycemia
  • Caution in patients with hepatic impairment
  • Monitor patients with a history of depression
  • Use with caution in patients with peripheral vascular disease
  • May mask signs of hyperthyroidism or hypoglycemia
  • Gradual withdrawal is recommended to avoid rebound hypertension

Pregnancy

Propranolol should only be used during pregnancy if the benefits outweigh the risks. It can affect fetal development and may cause bradycardia or respiratory issues in the neonate.

Breast-feeding

Propranolol is excreted in breast milk. Caution is advised when administered to a nursing mother, as it may affect the infant.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

  • 5 mg/1 ml solution for injection
  • 40 mg tablets
  • 80 mg tablets
BNF 85 (British National Formulary) p.187 BNF for Children 2019-2020 p.128 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: propranolol

PubChem CID 4946

Molecular formula: C16H21NO2

Mechanism of action

Propranolol is a nonselective β-adrenergic receptor antagonist. Blocking of these receptors leads to vasoconstriction, inhibition of angiogenic factors like vascular endothelial growth factor (VEGF) and basic growth factor of fibroblasts (bFGF), induction of apoptosis of endothelial cells, as well as down regulation of the renin-angiotensin-aldosterone system.

Pharmacodynamics

Propranolol is a beta-adrenergic receptor antagonist used to treat hypertension. Propranolol has a long duration of action as it is given once or twice daily depending on the indication. When patients abruptly stop taking propranolol, they may experience exacerbations of angina and myocardial infarctions.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.